挡不住了！10倍光纤牛股5天3板，市值突破2000亿！创新药集体走强，是反弹还是反转？

Market Overview - The A-share market showed resilience today, with the Shanghai Composite Index rising by 0.24% despite earlier declines of over 1%. The Shenzhen Component Index fell by 0.25%, and the ChiNext Index decreased by 0.68% [2][3] - The total trading volume in the Shanghai and Shenzhen markets reached 1.92 trillion yuan, an increase of 626 billion yuan compared to the previous trading day, with over 2800 stocks rising [3] Fiber Optics Sector - The fiber optics sector saw significant gains, with Longfly Fiber achieving five consecutive trading days of increases, reaching a historical high and a total market capitalization exceeding 200 billion yuan. The stock has increased over tenfold since early 2025 [6] - A report indicated that Chinese fiber optic cable manufacturers are experiencing a surge in overseas orders, with exports increasing by 51% year-on-year in the first two months. The domestic market prices for G.652.D single-mode fiber have surpassed 50 yuan per core kilometer, marking a seven-year high [7] - Analysts predict that the demand for 800G optical modules will continue to grow rapidly, with the development of 3.2T optical modules beginning as data transmission needs increase due to advancements in GPU and ASIC technologies [7] Nonferrous Metals Sector - The nonferrous metals sector, particularly aluminum, showed strong performance, with several companies reaching their daily price limits. The geopolitical situation in the Middle East has exacerbated global supply tensions, with predictions that aluminum prices could rise to $4000 per ton from the current $3300 per ton [11] - Chinese aluminum companies reported net profits exceeding 1 billion yuan, with some companies like Hongqiao Group and Chalco achieving profits in the hundred billion yuan range. The overall supply reduction trend in the aluminum market is expected to be irreversible [11] Innovative Pharmaceuticals Sector - The innovative pharmaceuticals sector continued its strong performance, with several companies, including Shuanglu Pharmaceutical and Lianhuan Pharmaceutical, reaching their daily price limits. The sector has seen significant growth, with a total of over $60 billion in authorized transactions in the first three months of the year [13][15] - The National Medical Products Administration reported that 10 innovative drugs have been approved in 2026, with a notable agreement between Eli Lilly and Insilico Medicine valued at $2.75 billion to develop AI-driven drugs for the global market [15] - Analysts emphasize the ongoing global competitiveness of Chinese innovative drugs, with increasing transaction volumes and values in overseas markets, indicating a strong potential for future growth and valuation increases [15]